Reflective of a dedicated focus on infection prevention and stringent hygiene standards in the healthcare sector, the global Endoscope Reprocessing Market has observed consequential growth. The market grew from a valuation of US$2.49 billion in 2024 to USD$2.71 billion in 2025, indicating a growth trajectory set to propel the market’s estimated value to US$4.24 billion by 2030. The robust Compound Annual Growth Rate (CAGR) of 9.4% from 2025 to 2030 underscores the thriving demand for effective endoscope reprocessing services.
The market’s expansion has been driven by several factors including the growing prevalence of gastrointestinal cancer and chronic illnesses globally. Accompanied by an increased number of endoscopic diagnostic and surgical procedures, the urgency for effective endoscope reprocessing measures is heightened. Furthermore, the necessary interventions by global health authorities to elevate reprocessing standards in response to the waking awareness of endoscope-associated infections (EAIs), has contributed towards market growth.
The marked market progress has been further supported by automated high-level disinfection systems, breakthroughs in reprocessing consumables, and an increase in hospital investments in centralized sterile processing departments (CSPDs). Thus, these factors coupled with rapid healthcare infrastructure and infection control practices improvement in emerging economies, present a ripe landscape for endoscope reprocessing manufacturers.
The endoscope reprocessing market can be segmented into equipment, consumables, and endoscope tracking solutions. Consumables are predicted to be the fastest-growing segment due to the recurring demand for disinfectants, detergents, and other essentials in every cycle of endoscope reprocessing. This regular consumption is fueled by an increase in the volume of endoscopic surgeries and diagnostic procedures. Additionally, stricter regulatory guidelines for disinfection, ongoing product advancements in high-level disinfectants, and enzymatic formulations have further boosted this segment’s growth.
The market is also segmented by user category into hospitals & Ambulatory Surgery Centers (ASCs), specialty clinics, and other end users. Hospitals & ASCs held the lion’s share of the market in 2024 due to the high volume of endoscopic procedures performed in these settings, advanced reprocessing infrastructure, and adherence to infection control guidelines. Furthermore, the rising number of hospital admissions in conjunction with gastrointestinal, respiratory, and urological disorders—especially among the aging population—has further escalated endoscope usage and thus, the demand for reprocessing products.
Geographically, the market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. North America led the global market in 2024 due to the high number of endoscopic procedures conducted each year, particularly in the US and Canada. The regional leadership is strengthened by dominant market players including Ecolab, CONMED Corporation, Micro-Scientific, ARC Healthcare Solutions, and Metrex Research. These entities reportedly drive innovation, launch new products, and facilitate large-scale adoption via strategic partnerships and vast distribution networks, consequently boosting the regional market growth.
Prominent players comprising ASP (US), Olympus Corporation (Japan), Ecolab (US), STERIS (Ireland), Getinge AB (Sweden), among others, significantly contribute to the global endoscope reprocessing market. For instance, STERIS, a market leader, provides products and services emphasizing on infection prevention, operating over 100 countries worldwide. The company’s focus on Research & Development (R&D), collaborations with other players, and plans for geographical and marketing expansion, underscore its commitment to long-term growth.
Similar commitments are exhibited by other key players such as ASP and Olympus Corporation. ASP, ranking as the second-largest player in 2024, is dedicated to creating the safest environment for patients and healthcare providers globally. Olympus, the third leading player in 2024, heavily invests in R&D activities to introduce innovative hygiene and safety systems.